---
document_datetime: 2023-09-21 17:03:41
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/inovelon-h-c-660-x-17-epar-assessment-report-extension_en.pdf
document_name: inovelon-h-c-660-x-17-epar-assessment-report-extension_en.pdf
version: success
processing_time: 7.5545075
conversion_datetime: 2025-12-28 02:32:29.376228
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

EMA/820313/2011 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Inovelon

rufinamide

Procedure No.:

EMEA/H/C/000660/X/0017

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

FaGLYPH&lt;31&gt;simile

+44 (0)20 7523 7455

E-mail

info@ema.europa.eu

Website

www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1 .............................................4 Background information on the procedure                                                                                                                                                   | 1 .............................................4 Background information on the procedure                                                                                                                                                   | 1 .............................................4 Background information on the procedure                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1 .................................................................................. 4 Submission of the dossier                                                                                                                         | 1.1 .................................................................................. 4 Submission of the dossier                                                                                                                         | 1.1 .................................................................................. 4 Submission of the dossier                                                                                                                         |
| 1.2 ...................................................... 4 Steps taken for the assessment of the product 2 ...............................................................................5 Scientific discussion                        | 1.2 ...................................................... 4 Steps taken for the assessment of the product 2 ...............................................................................5 Scientific discussion                        | 1.2 ...................................................... 4 Steps taken for the assessment of the product 2 ...............................................................................5 Scientific discussion                        |
| 2.1 ..................................................................................................... 5 Introduction                                                                                                                   | 2.1 ..................................................................................................... 5 Introduction                                                                                                                   | 2.1 ..................................................................................................... 5 Introduction                                                                                                                   |
| 2.2 ................................................................................................. 6 Quality aspects                                                                                                                    | 2.2 ................................................................................................. 6 Quality aspects                                                                                                                    | 2.2 ................................................................................................. 6 Quality aspects                                                                                                                    |
| 2.2.1 .................................................................................................. 6 Introduction                                                                                                                    | 2.2.1 .................................................................................................. 6 Introduction                                                                                                                    | 2.2.1 .................................................................................................. 6 Introduction                                                                                                                    |
| 2.2.2 ........................................................................................... 6 Active Substance                                                                                                                       | 2.2.2 ........................................................................................... 6 Active Substance                                                                                                                       | 2.2.2 ........................................................................................... 6 Active Substance                                                                                                                       |
| 2.2.3 ............................................................................... 7 Finished Medicinal Product                                                                                                                         | 2.2.3 ............................................................................... 7 Finished Medicinal Product                                                                                                                         | 2.2.3 ............................................................................... 7 Finished Medicinal Product                                                                                                                         |
| 2.2.4 ............................. 9 Discussion on chemical, pharmaceutical and biological aspects                                                                                                                                        | 2.2.4 ............................. 9 Discussion on chemical, pharmaceutical and biological aspects                                                                                                                                        | 2.2.4 ............................. 9 Discussion on chemical, pharmaceutical and biological aspects                                                                                                                                        |
| 2.2.5 .................... 10 Conclusions on the chemical, pharmaceutical and biological aspects                                                                                                                                           | 2.2.5 .................... 10 Conclusions on the chemical, pharmaceutical and biological aspects                                                                                                                                           | 2.2.5 .................... 10 Conclusions on the chemical, pharmaceutical and biological aspects                                                                                                                                           |
| 2.2.6 .............................................. 10 Recommendation for future quality development                                                                                                                                      | 2.2.6 .............................................. 10 Recommendation for future quality development                                                                                                                                      | 2.2.6 .............................................. 10 Recommendation for future quality development                                                                                                                                      |
| 2.3 ......................................................................................... 10 Non-clinical aspects                                                                                                                      | 2.3 ......................................................................................... 10 Non-clinical aspects                                                                                                                      | 2.3 ......................................................................................... 10 Non-clinical aspects                                                                                                                      |
| 2.3.1 ................................................................................................ 10 Introduction                                                                                                                     | 2.3.1 ................................................................................................ 10 Introduction                                                                                                                     | 2.3.1 ................................................................................................ 10 Introduction                                                                                                                     |
| 2.3.2 ...................................................... 10 Ecotoxicity/environmental risk assessment                                                                                                                                  | 2.3.2 ...................................................... 10 Ecotoxicity/environmental risk assessment                                                                                                                                  | 2.3.2 ...................................................... 10 Ecotoxicity/environmental risk assessment                                                                                                                                  |
| 2.3.3 ............................................................. 12 Conclusion on the non-clinical aspects                                                                                                                              | 2.3.3 ............................................................. 12 Conclusion on the non-clinical aspects                                                                                                                              | 2.3.3 ............................................................. 12 Conclusion on the non-clinical aspects                                                                                                                              |
| 2.4 ............................................................................................... 12 Clinical aspects                                                                                                                    | 2.4 ............................................................................................... 12 Clinical aspects                                                                                                                    | 2.4 ............................................................................................... 12 Clinical aspects                                                                                                                    |
| 2.4.1 ................................................................................................ 12 Introduction                                                                                                                     | 2.4.1 ................................................................................................ 12 Introduction                                                                                                                     | 2.4.1 ................................................................................................ 12 Introduction                                                                                                                     |
| 2.4.2 ......................................................................................... 12 Pharmacokinetics                                                                                                                        | 2.4.2 ......................................................................................... 12 Pharmacokinetics                                                                                                                        | 2.4.2 ......................................................................................... 12 Pharmacokinetics                                                                                                                        |
| 2.4.3 ......................................................... 16 Conclusions on clinical pharmacokinetics                                                                                                                                | 2.4.3 ......................................................... 16 Conclusions on clinical pharmacokinetics                                                                                                                                | 2.4.3 ......................................................... 16 Conclusions on clinical pharmacokinetics                                                                                                                                |
| 2.5 ............................................................................................... 16 Clinical efficacy                                                                                                                   | 2.5 ............................................................................................... 16 Clinical efficacy                                                                                                                   | 2.5 ............................................................................................... 16 Clinical efficacy                                                                                                                   |
| 2.5.1 .................................... 16 Study E2080-A001-301 Summary of main study results                                                                                                                                           | 2.5.1 .................................... 16 Study E2080-A001-301 Summary of main study results                                                                                                                                           | 2.5.1 .................................... 16 Study E2080-A001-301 Summary of main study results                                                                                                                                           |
| 2.5.2 ....................................................................... 16 Conclusions on clinical efficacy                                                                                                                          | 2.5.2 ....................................................................... 16 Conclusions on clinical efficacy                                                                                                                          | 2.5.2 ....................................................................... 16 Conclusions on clinical efficacy                                                                                                                          |
| 2.6.1 ......................................................................... 17 Conclusions on clinical safety                                                                                                                          | 2.6.1 ......................................................................... 17 Conclusions on clinical safety                                                                                                                          | 2.6.1 ......................................................................... 17 Conclusions on clinical safety                                                                                                                          |
| 2.6 ................................................................................................. 17 Clinical safety 2.7 ..................................................................................... 17 Risk Management Plan | 2.6 ................................................................................................. 17 Clinical safety 2.7 ..................................................................................... 17 Risk Management Plan | 2.6 ................................................................................................. 17 Clinical safety 2.7 ..................................................................................... 17 Risk Management Plan |
| 2.8 ..................................................................... 20 Update of the Product information                                                                                                                             | 2.8 ..................................................................... 20 Update of the Product information                                                                                                                             | 2.8 ..................................................................... 20 Update of the Product information                                                                                                                             |
| 3 ......................................................................20 Benefit-Risk Assessment                                                                                                                                         | 3 ......................................................................20 Benefit-Risk Assessment                                                                                                                                         | 3 ......................................................................20 Benefit-Risk Assessment                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AEDs

Anti Epileptic drugs

AUC

Area Under the Curve

CGP

Good Clinical Practice

CHMP

Committee for Medicinal Products for Human Use

Cmax

Concentration maximum

CPPs

Critical process parameters

EC

European Commission

ECG

Electrocardiogram

EEG

Electroencephalogram

EMA

European Medicines  Agency

ERA

Environmental Risk Assessment

EU

European Union

EURAP

European and International Registry of Anti-epileptic

drugs in Pregnancy

EU-RMP

EU Risk Management Plan

GCP

Good Clinical Practice

HPLC

High Performance Liquid Chromatography

PDA

Photodiode Array

ITT

Intent To Treat

LGS

Lennox-Gastaut syndrome

OECD

Organization of Economic Co-operation and

Development

PARs

Proven acceptable ranges

PEC

Predicted-environmental-concentration

PET

Polyethylene Terephthalate

pH

Measure of acidity

Ph Eur

European Pharmacopoeia

PIBA

Press-in bottle adapter

PIP

Paediatric Investigation Plan

PKs

Pharmacokinetics

PP

Per-protocol

PSURs

Periodic Safety Update Report

RH

Relative Humidity

RMP

Risk Management Plan

SmPC

Summary of Product Characteristics

TEAEs

Treatment-Emergent Adverse Event

TLC

Thin Layer Chromatography

<div style=\"page-break-after: always\"></div>

## 1 Background information on the procedure

## 1.1 Submission of the dossier

The  applicant  Eisai  Ltd  submitted  on  23  September  2010  an  application  for  an  extension  of  the Marketing Authorisation to the European Medicines Agency (EMA) for Inovelon, pursuant to Article 19 of Commission Regulation (EC) No 1234/2008, Annex I.

Inovelon was designated as an orphan medicinal product EU/3/04/240 on 20 October 2004. Inovelon was  designated  as  an  orphan  medicinal  product  in  the  following  indication:  treatment  of  LennoxGastaut Syndrome.

## Information on Paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/153/2010 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Not applicable.

## Market Exclusivity

Not applicable.

## Scientific Advice/Protocol Assistance

The applicant did not seek scientific advice or Protocol Assistance at the CHMP.

## 1.2 Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was: Pierre Demolis.

-  The application was received by the EMA on 23 September 2010.
-  The procedure started on 20 October 2010.
-  The Rapporteur's first Assessment Report was circulated to all CHMP members on 13 January 2011 (Annex 1).
-  During the meeting on 17 February 2011, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 17 February 2011 (Annex 2).
-  The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  27  April 2011.

<div style=\"page-break-after: always\"></div>

-  The  Rapporteur  circulated  the  Assessment  Report  on  the  applicant's  responses  to  the  List  of Questions to all CHMP members on 17 June 2011 (Annex 3).
-  During the CHMP meeting on 20-23 June 2011, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant (Annex 4).
-  The applicant submitted the responses to the CHMP List of Outstanding Issues on 22 August 2011.
-  The  Rapporteur  circulated  the  Assessment  Report  on  the  applicant's  responses  to  the  list  of outstanding issues to all CHMP members on 14 September 2011 (Annex 5).
-  During the meeting on 19-22 September 2011, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  the  extension  of Marketing Authorisation to Inovelon on 22 September 2011.

## 2 Scientific discussion

## 2.1 Introduction

Lennox-Gastaut syndrome (LGS) is rare and is one of the most severe forms of childhood epilepsy. The syndrome usually affects children between the ages of 1 and 8 years (typically between 3 and 5 years), but occasionally has its onset in children who are more than 8 years old. LGS begins in childhood but continues to manifest into adulthood in a large number of patients and has a significant morbidity and mortality. The hallmarks of the disease include the following triad:

-  The  presence  of  multiple  seizure  types:  the  most  characteristic  are  tonic-atonic  seizures  and atypical  absences,  but  tonic-clonic,  myoclonic,  and  partial  seizures  are  also  frequently  present. Tonic-atonic  seizures  often  provoke  sudden  falls  (commonly  called  drop  attacks)  and  result  in injuries.
-  The presence of generalized discharges with slow spike-and-wave complexes in the EEG.
-  The presence of mental retardation or a learning disability. In general, this is  represented  by  a static encephalopathy, although the mental status may worsen in the course of the disease due to multiple  causes,  such  as  very  frequent  occurrence  of  seizures,  sometimes  subclinical,  frequent head  trauma  from  the  falls  associated  with  seizures  (drop  attacks),  and  undesirable  cognitive effects  of  the  high  doses  of  antiepileptic  drugs  (AEDs)  used  to  treat  this  very  refractory  type  of epilepsy.

Patients with LGS often receive polytherapy due to the lack of full response to any single AED.

Inovelon (rufinamide) tablets were authorised in the EU on 16 January 2007 for use as ' adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years of age and older and adults.'

The dose of Inovelon depends on the patient's age and weight and whether the patient is also taking valproate. Treatment generally starts with a daily dose of 200 or 400 mg and may be increased as frequently  as  every  other  day  (up  to  the  maximum  recommended  dose)  according  to  the  patient's response to treatment.

As a post-approval commitment Eisai agreed to develop a 'child-friendly' formulation.

Eisai Limited submitted an application for Inovelon 40 mg/mL, oral suspension as a line extension to the already marketed Inovelon 100, 200 and 400 mg, film-coated tablets.

<div style=\"page-break-after: always\"></div>

Inovelon oral suspension is intended to be used for treatment in the same indication and the same dose range to the film-coated tablets, but affords a more convenient presentation for administration to young children and for those who cannot swallow tablets.

## Aspects on the product and its development

Rufinamide modulates the activity of sodium channels, prolonging their inactive state. Rufinamide is active in a range of animal models of epilepsy.

In the European Union, Rufinamide is currently available as tablets, with three strengths being on the market: 100 mg, 200 mg and 400 mg. For this new pharmaceutical form under review, a marketing authorization is sought for a unique strength (40 mg/mL). Since the oral suspension is intended for use at the same dose amounts as already approved for tablets, no specific characterization of rufinamide PKs  is  needed  except  the  demonstration  of  bioequivalence  of  the  currently  used  tablets  and  the proposed oral suspension.

The proposed dose range is similar to the film-coated tablets given daily in two divided doses. This dosage  form  affords  compliance  and  flexibility  of  dosing  from  100  mg  (2.5  mL)  administered  by  a graduated oral syringe to 2000 mg (50mL) (5 ml of suspension is equivalent to one 200 mg tablet).

No new non-clinical data were submitted.

The RMP has been revised in conformity with the EU-RMP template, to include both forms (tablets and oral suspension).

## 2.2 Quality aspects

## 2.2.1 Introduction

The drug substance rufinamide, is a triazole derivative used as an antiepileptic drug (AED), structurally unrelated to currently marketed AEDs.

This is an extension to include an additional dosage form developed for children and for those who are unable  or  prefer  not  to  swallow  a  tablet.  The  product  is  formulated  as  a  preserved,  non-sterile multidose orange flavoured liquid suspension formulation containing rufinamide 40 mg/mL.

The product is presented as a 460 mL fill into a 500 mL o-PET bottle with a child-resistant PP closure together  with  an  oral  dosing  syringe  with  a  press-in  bottle  adaptor  (PIBA)  to  deliver  200  mg  of rufinamide as a 5 mL dose (or increments thereof).

For a full list of excipients refer to the SmPC.

## 2.2.2 Active Substance

The drug substance, rufinamide, used to manufacture the oral suspension is identical in all respects (synthesis, manufacturer, specification including bulk density etc) to that used in the manufacture of the currently registered Inovelon film-coated tablets 100 mg, 200 mg and 400 mg. A new reference standard has been established and this is the only additional information provided.

<div style=\"page-break-after: always\"></div>

## 2.2.3 Finished Medicinal Product

## Pharmaceutical Development

The active substance is chemically stable and neutral - rufinamide does not act as a base or acid in aqueous solution (not dissociating). It is insoluble in aqueous solvent with low solubility in water and in gastric and intestinal fluid. Because of the low solubility of rufinamide, a suspension formulation was selected as the candidate formulation.

Rufinamide is not hygroscopic and does not absorb water up to 95% relative humidity (at 25°C). There are four known polymorphic forms. The same thermodynamically stable form is used in all batches for process  development  studies  and  clinical  investigations.  The  presence  of  rufinamide  does  not significantly impact the pH of the suspension formulation.

No  compatibility  issues  with  the  excipients  have  been  found.  The  choice  of  excipients  is  based  on pharmaceutical technological experience gained from development of similar products. The excipients selected  are  of  pharmacopoeial  grade  except  for  the  orange  flavour  which  is  supplied  by  a  global vendor.  All  excipients  are  well  accepted  for  use  in  pharmaceuticals  and  are  standard  ingredients  in suspension formulations.

The  preservative  system  comprises  methylparaben,  propylparaben  and  potassium  sorbate  and  was designed to secure an in-use shelf life of 90 days after first opening of the bottle. The preservative system has been developed taking into account the anti microbial and physicochemical properties as well as manufacturing aspects. Although the exact quantities used were not fully justified, the mixture of  the  preservatives  is  commonly  used  to  achieve  preservative  efficacy  and  the  preservative effectiveness  has  been  shown.  An  expert  statement  on  the  safety  of  parabens  species  in  oral formulations was provided. However propylparaben is no longer permitted in the EU for use in food products. Therefore, the applicant has committed to develop a paraben free formulation post-approval. It  is  considered that the requested reformulation could be done post-approval without compromising the  safety  of  the  product  or  otherwise  affecting  the  benefit  /  risk  balance.  A  change  management protocol has been submitted and an agreeable time frame was proposed.

Inovelon  oral  suspension  contains  propylene  glycol  as  a  solvent  for  parabens  since  parabens  are relatively difficult to dissolve in water. An expert statement on the safety of propylene glycol was also presented.

Anhydrous citric acid is added to the formulation to maintain the pH at approximately 4.0 where the performance of these preservatives is optimal.

It  was  demonstrated  that  the  oral  suspension  has  satisfactory  performance  of  preservative  efficacy according to Ph Eur acceptance criteria.

The artificial  orange flavour is added in consideration of palatability in younger children. Samples of different flavours were evaluated and orange was finally selected. An expert statement on the safety of the orange flavour was provided. The orange flavour consists of limonene, maize maltodextrin, alpha tocopherol and benzyl alcohol.

Non-crystallizing sorbitol solution, 70% is added as a sweetening agent in consideration of palatability in younger children. Sorbitol is commonly used in paediatric formulations as a sweetener. The safety of sorbitol in paediatric formulations was properly discussed.

The  container  closure  system  intended  for  marketing  was  evaluated  using  both  development  and commercial bottles and it was shown that the bottle provided adequate protection against moisture and light.  The  compatibility  of  the  container  closure  system  and  press-in  bottle  adapter  (PIBA)  was

<div style=\"page-break-after: always\"></div>

demonstrated showing adequate protection without any potential contamination from extractables or leachables. Inovelon oral suspension compatibility with the oral syringe and with a measuring cup for up to 6 hours at ambient conditions has also been shown.

A critical aspect in product manufacture is product homogeneity throughout the whole manufacturing process and for administration (dose uniformity) of the dosage form. A relative bioavailability study confirmed  bioequivalence  between  400  mg  tablets  and  10  mL  of  suspensions  with  different  particle sizes and dissolution rates. These results indicated that particle size and dissolution rate is not critical to  the  bioavailability.  The  dissolution  method  has  been  optimised  and  shown  to  be  discriminatory. Further, a correlation between particle size and dissolution has been established and only dissolution testing will be used as a finished product control method. Particle size will be checked at the end of the drug substance homogenization process by laser diffraction as an in-process test.

Specific  gravity  is  also  employed  as  another  in-process  test.  The  specific  gravity  data  are  used  to adjust the filling operation. The criteria for the specific gravity was determined based on the results from the process development batches.

## Adventitious agents

None of the excipients are derived from animal and/or human sources.

## Manufacture of the product

Inovelon oral suspension is manufactured using a conventional process for oral suspension products comprising four main steps.

A risk assessment was performed for the manufacturing process. Risk levels were assigned by process development  studies.  Proven  acceptable  ranges  (PARs)  and  proposed  operating  conditions  for  the homogenization process, final mixing, filtration process and mixing before filling were evaluated and established. The risk levels were mitigated by setting PARs for each critical process parameters (CPPs) or by setting the CPPs to constant values based on the process development studies. Results of the comparative  bioavailability  study  with  the  tablets  also  contributed  to  mitigate  the  risk  level  by  a decrease of the severity level of particle size and dissolution rate. Bulk holding time was determined by an appropriate study.

Process validation has been performed on three consecutive commercial scale batches manufactured by the proposed manufacturer using the proposed manufacturing conditions.

In addition to in-process controls, additional tests were conducted to compliment the information on the reproducibility and robustness of the manufacturing process.

The  manufacturing  process  is  satisfactorily  described  and  the  proposed  in-process  controls  are adequate. The results demonstrate that the manufacturing process established throughout the process development studies is able to consistently yield product with desirable quality.

## Product specification

The  release  and  shelf  life  specifications  for  Inovelon  oral  suspension  include  tests  and  limits  for appearance  (visual),  identification  (TLC,  HPLC-PDA),  pH  (Ph.  Eur.),  dissolution  (Ph.  Eur.),  related substances (HPLC), assay (HPLC), assay for preservatives (HPLC), viscosity (viscometer) and microbial limits (Ph. Eur.).

Batch analysis data are provided from seven batches of Inovelon oral suspension manufactured by the proposed manufacturer and three batches manufactured by another manufacturer. The batches were

<div style=\"page-break-after: always\"></div>

tested  according  to  the  specification  with  an  additional  test  for  particle  size.  All  batches  met  the requirement for each acceptance criteria and demonstrated good batch-to-batch consistency.

## Stability of the product

Stability studies have been performed on six full scale batches, and three supportive stability batches.

Studies on development batches include those studied under long-term conditions (30°C / 65% RH) for up to 12 months and accelerated conditions (40°C / 75% RH) for six months stored in the upright and inverted position. There was no significant change in any of the analytical test results except the assay for  potassium  sorbate.  Potassium  sorbate  was  found  to  decrease,  but  complies  with  the  shelf  life specification. There was no difference between the stability results of the samples stored in the upright orientation and the inverted orientation. It was found that the cap with liner did not affect the stability.

Photostability studies were conducted on samples in the upright position in bottles without a cover or covered  with  aluminium  foil  (dark  control).  No  changes  were  observed  and  all  results  met  the acceptance  criteria.  Photostability  testing  results  showed  that  light  had  no  influence  on  the  quality; hence no special storage precautions are required in relation to light.

In-use stability was conducted on samples in the upright position. No significant change was observed during storage for 90 days at 30°C / 65% RH except for a decreasing trend for potassium sorbate. The decrease of potassium sorbate did not affect the preservative efficacy.

The supportive stability studies were preformed under long-term conditions (30°C / 65% RH) for up to 36  months  and  accelerated  conditions  (40°C  /  75%  RH)  for  six  months,  stored  in  the  upright  and inverted position. There was no significant change in any of the analytical test results except the assay for potassium sorbate, but microbial limits and preservatives efficacy results remained unchanged.

Photostability studies were conducted in the upright position, performed using 1.2 million lux hours on bottles without a cover. No changes were observed in the suspension exposed to light.

In-use stability was conducted on samples stored in the upright position. No significant change was observed during storage for 90 days. There was no difference between using PIBA and not using PIBA.

Freeze-thaw and temperature cycling studies have been conducted. These conditions had no impact on the  quality  of  the  drug  product.  In  addition,  an  18  month  refrigerated  stability  study  has  been conducted.

Based on the results from all of the stability studies, the proposed shelf life and in-use shelf life when stored in the original container under the proposed storage conditions is accepted.

## 2.2.4 Discussion on chemical, pharmaceutical and biological aspects

Information  on  development,  manufacture  and  control  of  the  drug  substance  and  drug  product  has been  presented  in  a  satisfactory  manner.  The  results  of  tests  carried  out  indicate  satisfactory consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in the clinic.

<div style=\"page-break-after: always\"></div>

## 2.2.5 Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC.  Physicochemical  and  biological  aspects  relevant  to  the  uniform  clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6 Recommendation for future quality development

In the context of the obligation of the applicant to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

The applicant has committed to develop a paraben free formulation post-approval. It is considered that the requested reformulation could be done post-approval. A change management protocol has been submitted and an agreeable time frame was proposed.

## 2.3 Non-clinical aspects

## 2.3.1 Introduction

No new non-clinical data have been submitted in the application, which was considered acceptable by the CHMP.

## 2.3.2 Ecotoxicity/environmental risk assessment

The applicant has provided an ERA including a Phase I with calculation of a PECsurfacewater based on a refined Fpen. Moreover the ERA includes parts of a Phase II assessment.

The  Fpen  refinement  and  the  resulting  PEC  calculation  provided  by  the  applicant  is  based  on prevalence  data  of  the  disease  (number  of  patients)  and  on  additional  data  (number  of  average treatment days per year per patient, Eisai product market share). Taking into consideration all these data  together,  the  refined  PECsurfacewater  results  in  a  value  below  the  action  limit  of  0.01µg/l. However, this approach was not considered acceptable. According to the Guideline on the environmental  risk  assessment  of  medicinal  products  for  human  use  EMEA/CHMP/4447/00,  only prevalence data of the disease are acceptable for a PEC refinement in Phase I. If only the prevalence data are taken into consideration the refined PECsurfacewater will exceed the action limit for a Phase II assessment.

In the context of technical and scientific progress, the CHMP recommends that the applicant completes the Phase II assessment as described below.

The currently provided sludge respiration test, the modified Sturm test and the fresh water algal test are  acceptable  for  risk  assessment.  The  tests  were  already  assessed  during  the  authorisation procedure for Inovelon tablets. Nevertheless, because the active substance rufinamide was not readily biodegradable in the provided modified Sturm test (OECD 301 B) a test on Transformation in aquatic sediment systems (OECD 308) is necessary. Thus, the applicant should update the ERA by completing a  Phase  II  assessment  according  to  the  requirements  of  the  guideline  EMEA/CHMP/4447/00,  by  a Daphnia reproduction test (OECD 211) and a Fish early life stage test (OECD 210).

<div style=\"page-break-after: always\"></div>

## Table 1 Summary of main study results

## Substance (INN/Invented Name): rufinamide (INOVELON)

CAS-number (if available):

PBT screening

Result

Conclusion

Bioaccumulation potential- log K ow

OECD 107

0.65

Potential PBT

N

PBT-assessment

Parameter

Result relevant for conclusion

Conclusion

log K ow

0.65

not B

Bioaccumulation

BCF

not available

Persistence

DT50

or

ready

biodegradability

7-9%

at

Day

29

in

Modified Sturm Test

P

PBT-statement :

The compound is not considered as PBT nor vPvB

Phase I

Calculation

Value

Unit

Conclusion

PEC

surfacewater

,

default

or

refined

(e.g.

prevalence,

literature)

Default

(Refined

Fpen

approach

used

in

the

ERA was not accepted)



g/L

&gt;  0.01  threshold

Y

Other concerns (e.g. chemical

class)

N

## Phase II Physical-chemical properties and fate

Study type

Test protocol

Results

Remarks

Ready Biodegradability Test

OECD 301B

7-9% at Day 29

Modified

Sturm

Test

## Phase IIa Effect studies

Study type

Test

protocol

Endpoint

value

Unit

Remarks

Algae,

Growth

Inhibition

Test/

Species

OECD 201

NOEC

&gt;33 000

µg/L

Species

Selenastrum

capricornutum

Daphnia

sp

.

('static test')

OECD 202

NOEC

immobilisation

&gt;100 000

µg/L

Conducted

at

max

solubility

in water

Activated  Sludge,  Respiration

Inhibition Test

OECD 209

EC

µg/L

No

toxicity

to

wastewater

bacteria

at

concentration

of 100 000 µg/L

<div style=\"page-break-after: always\"></div>

## 2.3.3 Conclusion on the non-clinical aspects

No new non-clinical data have been submitted in the application, which was considered acceptable by the CHMP.

The applicant has provided a revised ERA including a Phase I with calculation of a PECsurfacewater Despite the request from the CHMP to conduct additional studies to complete the Phase II assessment, it  was  considered that Inovelon oral suspension will be interchangeable with the currently marketed form, but will not lead to an increased consumption of this orphan drug.

In the context of technical and scientific progress, the CHMP recommends that the applicant completes the Phase II assessment.

The  results  from  the  additional  studies  were  not  considered  required  by  the  Committee  before  the adoption of the positive CHMP opinion and it is confirmed that this application complies with Article 6 of Regulation  (EC)  No  726/2004  having  regard  to  the  requirements  of  Article  8(3)  (ca)  of  Directive 2001/83.

## 2.4 Clinical aspects

## 2.4.1 Introduction

The marketing approval for Inovelon oral suspension is being sought on the basis of bioequivalence with the current marketed tablets. The primary data to support bioequivalence comes from the single clinical study, E2080-E044-003, as the final market image suspension was tested in this study.

A second study (study CRUF331-0102) was also submitted. In this latter study performed in 1999 by NOVARTIS  (the  former  owner  of  the  rufinamide  patent)  a  prototype  of  an  oral  suspension  earlier developed for the US market had been tested versus a comparator also developed for the US market. This study could not be considered relevant for the application under review.

To support the safety package the applicant submitted also a double-blind, placebo-controlled, parallelgroup  study  of  the  rufinamide  tablet  (E2080-A001-301;  referred  to  as  Study  301)  in  subjects  with partial onset seizures currently inadequately treated with a maximum of three AEDs.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The  applicant  has  provided  a  statement  to  the  effect  that  the  studies  conducted  in  support  of  this application  were  carried  out  inside  the  European  Union  in  accordance  with  the  ethical  standards  of Directive 2001/20/EC.

## 2.4.2 Pharmacokinetics

The Pharmacokinetics of the product are described below, as reflected in the Product Information:

## Absorption

Maximum plasma levels are reached approximately 6 hours after administration. Peak concentration (Cmax) and plasma AUC of rufinamide increase less than proportionally with doses in both fasted and fed healthy subjects and in patients, probably due to dose-limited absorption behaviour. After single doses,  food  increases  the  bioavailability  (AUC)  of  rufinamide  by  approximately  34%  and  the  peak plasma concentration by 56%.

<div style=\"page-break-after: always\"></div>

## Distribution

In in-vitro studies, only a small fraction of rufinamide (34%) was bound to human serum proteins with albumin accounting for approximately 80% of this binding. This indicates minimal risk  of  drug-drug interactions  by  displacement  from  binding  sites  during  concomitant  administration  of  other  drugs. rufinamide was evenly distributed between erythrocytes and plasma.

## Biotransformation

Rufinamide  is  almost  exclusively  eliminated  by  metabolism.  The  main  pathway  of  metabolism  is hydrolysis of the carboxylamide group to the pharmacologically inactive acid derivative CGP 47292.

Cytochrome P450-mediated metabolism is very minor. The formation of small amounts of glutathione conjugates cannot be completely excluded.

Rufinamide  has  demonstrated  little  or  no  significant  capacity  in-vitro  to  act  as  a  competitive  or mechanism-based  inhibitor  of  the  following  human  P450  enzymes:  CYP1A2,  CYP2A6,  CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 or CYP4A9/11-2.

## Elimination

The  plasma  elimination  half-life  is  approximately  6-10  hours  in  healthy  subjects  and  patients  with epilepsy. When given twice daily at 12-hourly intervals, rufinamide accumulates to the extent predicted by its terminal half-life, indicating that the pharmacokinetics of rufinamide are time independent (i.e. no auto induction of metabolism).

In a radiotracer study in three healthy volunteers, the parent compound (rufinamide) was the main radioactive component in plasma, representing about 80% of the total radioactivity, and the metabolite CGP 47292 constituting only about 15%. Renal excretion was the predominant route of elimination for drug related material, accounting for 84.7% of the dose.

## Linearity/non-linearity

The bioavailability of rufinamide is dependent on dose. As dose increases, the bioavailability decreases.

## Pharmacokinetics in special patient groups

## Sex

Population  pharmacokinetic  modelling  has  been  used  to  evaluate  the  influence  of  sex  on  the pharmacokinetics of rufinamide. Such evaluations indicate that sex does not affect the pharmacokinetics of rufinamide to a clinically relevant extent.

## Renal impairment

The pharmacokinetics of a single 400 mg dose of rufinamide were not altered in subjects with chronic and  severe  renal  failure  compared  to  healthy  volunteers.  However,  plasma  levels  were  reduced  by approximately  30%  when  haemodialysis  was  applied  after  administration  of  rufinamide,  suggesting that this may be a useful procedure in case of overdose.

## Hepatic impairment

No studies have been performed in patients with hepatic impairment and therefore Inovelon should not be administered to patients with severe hepatic impairment.

<div style=\"page-break-after: always\"></div>

## Children (2-12 years)

Children  generally  have  lower  clearance  of  rufinamide  than  adults,  and  this  difference  is  related  to body size.  Studies  in  new-born  infants  or  infants  and  toddlers  under  2  years  of  age  have  not  been conducted.

## Elderly

A  pharmacokinetic  study  in  elderly  healthy  volunteers  did  not  show  a  significant  difference  in pharmacokinetic parameters compared with younger adults.

## Overview of the bioequivalence studies

Two  bioequivalence  studies  are  provided  by  the  applicant:  Study  E2080-E044-003  and CRUF331-0102.

Study E2080-E044-003 is a randomized, open-label, 4-period crossover trial to compare the bioavailability  of  single  400  mg  doses  of  rufinamide  administered  as  the  marketed  tablet with 3 suspension formulations manufactured using different homogeneity speeds. Results are shown in Table 2.

From this study it could be concluded that each suspension is bioequivalent to the 400 mg tablet when administered under fed conditions. Therefore, the particles size appears not to be  critical  for  the  bioavailability  of  the  oral  suspension.  The  applicant  reassured  the Committee that rufinamide pharmacokinetics is still linear within the therapeutic range 100 to  400  mg  and  the  non  linearity  linked  to  the  low  solubility  of  the  drug  would  occur  for higher doses.

<div style=\"page-break-after: always\"></div>

Table 2: Statistical Analysis of PK Parameters from Study E2080-E044-003

|                      |                                              | TestSuspensionFormulations   | TestSuspensionFormulations   | TestSuspensionFormulations   |
|----------------------|----------------------------------------------|------------------------------|------------------------------|------------------------------|
| Parameter            |                                              | 1800 rpm                     | 2100 rpm                     | 3000 rpm                     |
| Cmax (ng/mL)         | Suspension least square mean (test)          | 4254.87                      | 4204.29                      | 4418.44                      |
|                      | Tablet least square mean (reference)         | 4840.24                      | 4840.24                      | 4840.24                      |
|                      | Ratio of treatment means (suspension/tablet) | 0.88                         | 0.87                         | 0.91                         |
|                      | 90%ConfidenceIntervalof ratio                | (0.84-0.92)                  | (0.83-0.91)                  | (0.88-0.95)                  |
| AUC(0-72h) (ng.h/mL) | Suspension least square mean (test)          | 74279.02                     | 73746.03                     | 73701.17                     |
|                      | Tablet least square mean (reference)         | 75960.48                     | 75960.48                     | 75960.48                     |
|                      | Ratio of treatment means (suspension/tablet) | 0.98                         | 0.97                         | 0.97                         |
|                      | 90%ConfidenceIntervalof Ratio                | (0.95-1.00)                  | (0.95-1.00)                  | (0.95-0.99)                  |
| AUC(0-inf) (ng.h/mL) | Suspension least square mean (test)          | 74668.44                     | 74101.81                     | 74085.66                     |
|                      | Tablet least square mean (reference)         | 76374.48                     | 76374.48                     | 76374.48                     |
|                      | Ratio of treatment means (suspension/tablet) | 0.98                         | 0.97                         | 0.97                         |
|                      | 90%ConfidenceIntervalof ratio                | (0.95-1.00)                  | (0.95-0.99)                  | (0.95-0.99)                  |

The  second  Study  CRUF331-0102  evaluated  the  relative  bioavailability  of  a  single  400  mg  dose  of rufinamide tablet under fed conditions, a single 400 mg dose of rufinamide oral suspension under fed conditions, or a single dose of 400 mg rufinamide oral suspension under fasted conditions. This study showed  that  the  rufinamide  oral  suspension  administered  with  food  was  bioequivalent  to  the rufinamide  tablet  administered  with  food.  Food  significantly  increases  the  systemic  exposure  of rufinamide suspension by 31%.

However,  in  this  study  102,  performed  in  1999  by  the  former  owner  of  the  rufinamide  patent (Novartis), the Test product was an oral suspension prototype developed for the US market and the comparator was a tablet manufactured by wet granulation and a pre-densification step also formulated for the US market. Therefore, this study could not be considered relevant for the current application in the EU.

<div style=\"page-break-after: always\"></div>

## 2.4.3 Conclusions on clinical pharmacokinetics

Given  that  rufinamide  delivered  as  10  mL  of  a  40  mg/mL  oral  suspension  formulation  has  been demonstrated to be bioequivalent to the 400 mg oral tablet formulation, the dosing recommendations for the oral suspension are the same as those approved for the marketed tablet.

## 2.5 Clinical efficacy

Efficacy of rufinamide was established in the original marketing authorisation application. There is no new  pertinent  efficacy  information  in  the  authorised  indication,  which  is  the  use  of  rufinamide  oral suspension as adjunctive therapy in subjects with LGS.

The applicant submitted a report from a clinical study E2080-A001-301 (referred to as Study 301). In this clinical trial, rufinamide has been evaluated for the treatment of refractory partial-onset seizures in a population of adolescents and adults. The formulation used in this study is however a tablet and the assessment of this data does not affect the assessment of the oral suspension nor is a new indication opted for, however the study is described below.

## 2.5.1 Study E2080-A001-301 Summary of main study results

Study  301  was  a  double-blind,  placebo-controlled,  parallel-group  study  of  rufinamide  given  as adjunctive therapy in adolescent and adult patients (12 to 80 years inclusive) with refractory partial seizures.

Three  hundred  and  fifty-seven  subjects  were  randomly  assigned  to  receive  rufinamide  (N=176)  or placebo (N=181). Three hundred and fifty-six subjects (176 in the rufinamide group and 180 in the placebo group) received at least 1 dose of double-blind medication and were included in the safety population. Three hundred and thirty-five subjects (160 in the rufinamide group and 175 in the placebo group) were included in the Intent-to-Treat (ITT) population.

For the ITT population, the median percentage change in total partial seizure frequency per 28 days during the Maintenance Phase relative to the Baseline Phase (the primary efficacy variable) was -23.25 in  the  rufinamide  group  and  -9.80  in  the  placebo  group  (p=0.007).  For  the  per-protocol  (PP) population,  the  median  percentage  change  was  -25.35  for  the  rufinamide  group  and  -10.45  for  the placebo group (p=0.005). Thus, the magnitude and direction of the results were consistent for the ITT and  PP  populations.  The  results  for  subgroups  of  the  subjects  based  on  age,  sex,  race,  and  dose achieved at the end of the Titration Phase were consistent with those for the ITT population.

The results for the secondary efficacy variables supported the results for the primary variable. A higher percentage of subjects in the rufinamide group (32.5%) than the placebo group (14.3%) experienced at  least  a  50%  reduction  in  partial  seizure  frequency  per  28  days  during  the  Maintenance  Phase relative to the Baseline Phase (odds ratio: 2.889; p&lt;0.001).

## 2.5.2 Conclusions on clinical efficacy

Efficacy of rufinamide was established in the original marketing authorisation application. There is no new pertinent efficacy information in the authorised indication.

The usefulness of the efficacy evaluation of this study for the current application is however limited as the formulation used in this study is a tablet and is conducted in a different indication.

<div style=\"page-break-after: always\"></div>

## 2.6 Clinical safety

The clinical safety data package to support this application came from:

-  a double-blind, placebo-controlled, parallel-group study of the rufinamide tablet (E2080-A001301; referred to as Study 301) in subjects with partial onset seizures currently inadequately treated with a maximum of three AEDs.
-  a  primary  randomized,  open-label,  4-period  crossover  trial  to  compare  bioavailability  of  the rufinamide oral suspension (E2080-E044-003; hereafter referred to as Study 003), and PK of rufinamide administered as a tablet formulation with three suspension formulations manufactured under different conditions of homogenization speeds).
-  and  a  supporting  randomized,  open-label,  3-way,  crossover  trial  to  compare  the  relative bioavailability  of  the  rufinamide  oral  suspension  single  400  mg  doses  of  rufinamide  oral suspension and single 400 mg doses of rufinamide tablet under fed conditions, and to evaluate the  effect  of  food  on  the  bioavailability  of  the  rufinamide  oral  suspension  (CRUF331  0102; hereafter referred to as Study 102).

Safety  results  in  Study  301  were  consistent  with  the  known  safety  profile  of  rufinamide  tablets. Nevertheless, the absolute lymphocyte count decreased in 15 subjects (9.3%) in the rufinamide group, compared  to  4  subjects  (2.3%)  in  the  placebo  group.  The  applicant  reassured  the  Committee performing  an  additional  search  of  the  safety  database  (excluding  study  -301)  that  reported  no incidences of lymphocytopenia and there have been no lymphocytopenia related safety signals in the post-marketing reports after marketing of rufinamide for 4 years in the EU and for 2 years in the US. The  applicant  was  however  requested  to  closely  monitor  lymphocytopenia  and  discuss  any  possible event in future PSURs.

For Study 003, TEAEs and treatment-related TEAEs were frequent (54.2% of all subjects and 37.5% of all subjects, respectively), mild to moderate  in  severity, and  manageable  or  reversible  with concomitant  medication.  Only  two  subjects  experienced  TEAEs  that  led  to  withdrawal;  both  were urinary  tract  infections  and  were  considered  not  related  to  treatment.  TEAEs  and  treatment-related TEAEs did not appear more frequent with a particular treatment and therefore, there appears to be no effect of homogeneity on safety. As exposure is the same for the three suspension formulations and the 400 mg tablet, there was no impact of the manufacturing conditions on safety.

No  new  safety  information  emerged  from  the  adverse  events  reported  in  study  102  in  the  healthy volunteers who received one dose of 400 mg rufinamide (tablet or oral suspension) under fasted or fed conditions. Adverse events reported with the oral suspension and with the tablet were comparable.

## 2.6.1 Conclusions on clinical safety

In summary, rufinamide was safe and well tolerated when administered as an oral suspension in both Study  003  and  Study  102.  However,  those  two  studies  were  bioequivalent  studies,  open  label  and performed  with  single  doses  in  low  number  of  healthy  volunteers.  The  data  in  Study  301  were consistent with those previously reported for rufinamide tablets.

## 2.7 Risk Management Plan

The applicant submitted an updated risk management plan.

## Summary of the risk management plan

<div style=\"page-break-after: always\"></div>

| Safety concern                                             | Proposed pharmacovigilance activities (routine and additional)   | Proposed risk minimization Activities (routine and additional)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Identified Risk: Rash and Hypersensitivity                 | Routine pharmacovigilance Registry Study                         | Warning in section 4.4 of the SmPC that serious antiepileptic drug hypersensitivity syndrome has occurred in association with rufinamide therapy. Signs and symptoms of this disorder were diverse; however, patients typically, although not exclusively, presented with fever and rash associated with other organ system involvement. Other associated manifestations included lymphadenopathy, liver function tests abnormalities, and haematuria. Because the disorder is variable in its expression, other organ system signs and symptoms not noted here may occur. This syndrome occurred in close temporal association to the initiation of rufinamide therapy and in the paediatric population. If this reaction is suspected, rufinamide should be discontinued and alternative treatment started. All patients who develop a rash while taking rufinamide must be closely monitored. Information on incidence also in Undesirable effects in section 4.8 of SmPC. |
| Identified Risk: Decreased Appetite and Weight Loss        | Routine pharmacovigilance                                        | Information on incidence in Undesirable effects in section 4.8 of SmPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Identified Risk: Vomiting                                  | Routine pharmacovigilance Registry Study                         | Information on incidence in Undesirable effects in section 4.8 of SmPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Potential Risk: Pregnancy and Associated Birth Defects     | Routine pharmacovigilance Pregnancy Registry                     | Warning in section 4.4 of the SmPC that women of childbearing potential must use contraceptive measures during treatment with Inovelon. Physicians should try to ensure that appropriate contraception is used, and should use clinical judgment when assessing whether oral contraceptives, or the doses of the oral contraceptive components, are adequate based on the individual patient's clinical situation (see Section 4.5). Warning to avoid rufinamide in pregnancy unless benefit outweighs the risks in section 4.6 of the SmPC.                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Potential Risk: Developmental and Maturation Impairment in | Routine pharmacovigilance Registry Study                         | Changes will be made to the SmPC if warranted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Safety concern                               | Proposed pharmacovigilance activities (routine and additional)   | Proposed risk minimization Activities (routine and additional)                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Children and Adolescents                     |                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Potential Risk: Adverse Effects on Cognition | Routine pharmacovigilance Registry Study                         | Changes will be made to the SmPC if warranted.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Potential Risk: Shortened QT interval on ECG | Routine pharmacovigilance                                        | Warning in section 4.4 of the SmPC that in a thorough QT study, rufinamide produced a decrease in QTc interval proportional to concentration. Although the underlying mechanism and safety relevance of this finding is not known, clinicians should use clinical judgment when assessing whether to prescribe rufinamide to patients at risk from further shortening their QTc duration (e.g. Congenital Short QT Syndrome or patients with a family history of such a syndrome). |
| Potential Risk: Suicide                      | Routine pharmacovigilance Registry Study                         | Changes will be made to the SmPC if warranted.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Medication Errors                            | Routine pharmacovigilance Registry Study                         | Changes will be made to the SmPC if warranted.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Missing Information: Elderly population      | Routine pharmacovigilance                                        | Since the pharmacokinetics of rufinamide are not altered in the elderly, dosage adjustment is not required in patients over 65 years of age. (Section 4.2 and Section 5.2 in SmPC).                                                                                                                                                                                                                                                                                                |
| Missing Information: Concomitant Medications | Routine pharmacovigilance Registry Study                         | Warning in section 4.5 of the SmPC about interactions.                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Missing Information: Pregnancy               | Routine pharmacovigilance Pregnancy registry                     | Warning in section 4.4 and section 4.5 of the SmPC that women of childbearing potential must use contraceptive measures                                                                                                                                                                                                                                                                                                                                                            |
| Missing Information: Hepatic Impairment      | Routine pharmacovigilance                                        | Section 4.2 of the SmPC notes that use in patients with hepatic impairment has not been studied. Caution and careful dose titration is recommended when treating patients with mild to moderate hepatic impairment. Therefore, use in patients with severe hepatic impairment is not recommended. Also noted in section 5.2 of SmPC.                                                                                                                                               |

The CHMP, having considered the data submitted for the new pharmaceutical form, was of the opinion that the pharmacovigilance activities in addition to the use of routine Pharmacovigilance, agreed for the currently marketed formulation were to be maintained to investigate further some of the safety concerns:

<div style=\"page-break-after: always\"></div>

-  Registry Study : European Registry of Anti-Epileptic Drug Use in Patients with LGS (E2080E044-401). Ongoing study. Planned Date for Submission of Final Data: December 2013.
-  Pregnancy registry : A pregnancy registry is being maintained by EURAP (European and International Registry of Anti-epileptic drugs in Pregnancy). Eisai provide financial support to EURAP in return for details of pregnancy cases collected and the reported outcomes.

No additional risk minimisation activities were required beyond those included in the product information in relation to the new formulation.

In addition, the MAH is requested to submit an updated version of the RMP in order to discuss and reflect the potential risk of the propylparaben contained in Inovelon on the reproductive system.

## PSUR cycle

The CHMP considered that the PSUR cycle should be amended based on the data submitted in the application and requested an additional yearly PSUR.

The next PSUR will cover the period from 16 January 2011 to 15 January 2012 and should be submitted no later than 15 March 2012.

## 2.8 Update of the Product information

Inovelon oral suspension is intended to be used for treatment in the same indication and the same dose range to the film-coated tablets, which has been reflected in the new presentations incorporated in the product information.

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3 Benefit-Risk Assessment

## Benefits

## Beneficial effects

Inovelon oral suspension is intended to be used for treatment in the same indication and the same dose range to the film-coated tablets, but affords a more convenient presentation for administration to young children  and  for  those  with  difficulties  in  swallowing  and  increases  the  treatment  options  for patients who prefer to not swallow a solid oral dosage form.

## Uncertainty in the knowledge about the beneficial effects

Rufinamide was safe and well tolerated in the 3 studies submitted to support the safety profile of the product and the results of the findings were consistent with the known safety profile of Rufinamide tablets. However, Study 301 has been performed with rufinamide tablets, and not oral suspension; and in patients with partial onset seizures, whereas rufinamide is currently authorized in the treatment of seizures associated with Lennox-Gastaut syndrome. In addition, safety data coming from the other 2 bioequivalence  studies  003  and  102  have  a  limited  significance,  since  these  were  bioequivalence studies, open label and performed in a low number of healthy volunteers.

<div style=\"page-break-after: always\"></div>

## Risks

## Unfavourable effects

Based on the favourable outcome of the Bioequivalence study comparing the new oral solution with the established tablet formulation, the same safety profile as the tablet presentation is expected.

## Uncertainty in the knowledge about the unfavourable effects

Although  at  present  many  medicinal  products  contain  propylparabens,  propylparaben  is  no  longer permitted in the EU for use in food products. It has been shown to exhibit an oestrogenic potential in vitro and effects on male fertility parameters have been observed in rat studies. Thus, considering that the product is intended for the paediatric population, the use of propylparaben represents a concern, which needs to be further elucidated.

While  a  consortium  of  companies  is  working  with  the  AFSSAPS  to  assess  the  potential  risk  of propylparaben on the reproductive system of the neonatal rat, the MAH has committed to develop a paraben free formulation post-approval, which was acceptable, in the light of the clinical need for the product in the small target population.

## Benefit-risk Balance

## Importance of favourable and unfavourable effects

The benefit-risk balance is considered positive.

## Benefit-risk balance

Lennox-Gastaut syndrome (LGS) is rare and is one of the most severe forms of childhood epilepsy and patients with LGS often receive polytherapy due to the lack of full response to any single AED.

Inovelon oral suspension provides additional treatment options for patients who have not sufficiently responded  to  other  AEDs,  and  rufinamide  has  shown  to  be  efficacious  as  adjunctive  treatment  of seizures associated with Lennox-Gastaut syndrome in children 4 years of age and older and adults.

The  development  of  a  suitable  oral  suspension  formulation  of  rufinamide  increases  the  treatment options for patients, particularly young children, with LGS. The oral suspension would also address the needs of older patients who are unable to or prefer not to swallow a solid oral dosage form. Patient compliance would also be expected to improve, especially in young children.

Inovelon oral suspension has been shown to be bioequivalent to the marketed 400 mg tablet. Based on these results, rufinamide oral suspension confers all the benefits of the tablets with respect to seizure control  but  offers  an  alternative  oral  formulation  for  ease  of  use  in  young  children  and  a  potential increase in patient compliance.

As there are potential risks  associated  to  the  use  of  the  preservative  propylparaben  that  cannot  be excluded,  the  applicant  has  committed  to  develop  a  paraben  free  formulation  after  adoption  of  the positive CHMP opinion, which was acceptable in the light of the clinical need for the product.

Overall, having considered the benefits of the new formulation and its comparable safety profile to the marketed tablets the CHMP considered that the benefit-risk balance of rufinamide oral solution  was favourable.

<div style=\"page-break-after: always\"></div>

## 4 Recommendations

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the benefit-risk balance of Inovelon oral suspension as adjunctive treatment of seizures associated with  Lennox-Gastaut  syndrome  was  favourable  and  therefore  recommended  the  granting  of  the extension of the Marketing Authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the Marketing Authorisation

## Risk Management System

The  MAH  must  ensure  that  the  system  of  pharmacovigilance,  presented  in  Module  1.8.1  of  the marketing authorisation, is in place and functioning before and whilst the product is on the market.

The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan of the Risk  Management  Plan  (RMP)  presented  in  Module  1.8.2  of  the  marketing  authorisation  and  any subsequent updates of the RMP agreed by the CHMP.

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).

In addition, an updated RMP should be submitted:

-  When  new  information  is received that may  impact  on  the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
-  Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
-  at the request of the EMA

## PSUR cycle

The PSUR cycle for the product will follow a yearly cycle until otherwise agreed by the CHMP.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

Not applicable

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.